Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Gene | CSF3R |
Variant | Q741* |
Impact List | nonsense |
Protein Effect | gain of function |
Gene Variant Descriptions | CSF3R Q741* results in a premature truncation of the Csf3r protein at amino acid 741 of 836 (UniProt.org). Q741* results in increased Csf3r cell surface expression, impaired receptor internalization, G-CSF hypersensitivity, elevated Stat5 activation, and is transforming in cell culture (PMID: 23656643, PMID: 28439110). |
Associated Drug Resistance | |
Category Variants Paths |
CSF3R mutant CSF3R act mut CSF3R Q741* |
Transcript | NM_000760.4 |
gDNA | chr1:g.36466647G>A |
cDNA | c.2221C>T |
Protein | p.Q741* |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_000760.4 | chr1:g.36466647G>A | c.2221C>T | p.Q741* | RefSeq | GRCh38/hg38 |
NM_172313 | chr1:g.36466647G>A | c.2221C>T | p.Q741* | RefSeq | GRCh38/hg38 |
NM_000760 | chr1:g.36466647G>A | c.2221C>T | p.Q741* | RefSeq | GRCh38/hg38 |
NM_172313.2 | chr1:g.36466647G>A | c.2221C>T | p.Q741* | RefSeq | GRCh38/hg38 |
NM_000760.3 | chr1:g.36466647G>A | c.2221C>T | p.Q741* | RefSeq | GRCh38/hg38 |
NM_172313.3 | chr1:g.36466647G>A | c.2221C>T | p.Q741* | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CSF3R T618I CSF3R Q741* | hematologic cancer | predicted - resistant | AZD1480 | Preclinical - Cell culture | Actionable | In a preclinical study, transformed hematologic cells co-expressing CSF3R T618I and CSF3R Q741* were resistant to treatment with AZD1480 in culture (PMID: 28031554). | 28031554 |
CSF3R T618I CSF3R Q741* | hematologic cancer | predicted - resistant | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed hematologic cells co-expressing CSF3R T618I and CSF3R Q741* were resistant to treatment with Jakafi (ruxolitinib) in culture (PMID: 28031554). | 28031554 |
CSF3R T618I CSF3R Q741* | hematologic cancer | predicted - resistant | Dasatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed hematologic cells co-expressing CSF3R T618I and CSF3R Q741* were resistant to treatment with Sprycel (dasatinib) in culture (PMID: 28031554). | 28031554 |
CSF3R N579Y CSF3R Q739* CSF3R Q741* | chronic neutrophilic leukemia | predicted - sensitive | Ruxolitinib | Preclinical - Patient cell culture | Actionable | In a preclinical study, Jakafi (ruxolitinib) treatment inhibited colony formation of hematopoietic progenitor cells isolated from the bone marrow of a patient with chronic neutrophilic leukemia harboring CSF3R N579Y, Q739*, and Q741* in culture (PMID: 36579444). | 36579444 |